10x Genomics
274 hedge funds and large institutions have $4.98B invested in 10x Genomics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 94 increasing their positions, 79 reducing their positions, and 31 closing their positions.
107% more call options, than puts
Call options by funds: $21M | Put options by funds: $10.2M
61% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 31
19% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 79
6% more funds holding
Funds holding: 258 → 274 (+16)
1% less capital invested
Capital invested by funds: $5.03B → $4.98B (-$49.6M)
1.8% less ownership
Funds ownership: 92.63% → 90.83% (-1.8%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$202M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$57.7M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$39.8M |
| 4 |
RI
RTW Investments
New York
|
+$28.9M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$264M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$56.4M |
| 3 |
SIM
SRS Investment Management
New York
|
-$45M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$37.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$27.5M |
TXG Hedge Fund Activity: Q2 2023 in Review
274 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2023, worth a combined $4.98B — down 0.99% from $5.03B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new TXG positions and 31 closed out — a net gain of 19 holders — while 94 added to existing stakes and 79 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $202M. The largest seller was Morgan Stanley, cutting an estimated $264M.
- 274 institutional investors held 10x Genomics (TXG) as of Q2 2023, up from 258 in Q1 2023.
- Funds reported $4.98B of 10x Genomics stock for Q2 2023, down 0.99% quarter-over-quarter.
- 50 funds opened new 10x Genomics positions in Q2 2023 and 31 closed out, a net change of +19 holders.
- The largest 10x Genomics buyer in Q2 2023 was Fidelity Investments, an estimated $202M added.
- The largest 10x Genomics seller in Q2 2023 was Morgan Stanley, an estimated $264M sold.
Based on aggregated 13F filings for Q2 2023.